Objectives: A multicentre surveillance of tigecycline activity against relevant pathogens in the UK.
Introduction
Tigecycline was registered in the European Union (EU) in April 2006, for parenteral use in complicated skin and soft tissue infections and complicated intra-abdominal infections caused by enterococci, staphylococci, streptococci and Enterobacteriaceae excluding Proteeae, which are intrinsically resistant. Its spectrum includes most Escherichia coli and Klebsiella spp. as well as methicillin-resistant staphylococci and other multiresistant Gram-positive bacteria. Acquired ribosomal protection [tet(M)] 1 
and efflux [tet(A-E)]
2,3 mechanisms affect other tetracyclines but not tigecycline.
Tigecycline has also been used for infections due to multiresistant Acinetobacter baumannii, against which it commonly has in vitro activity. While there are positive case reports, 4 it should be cautioned that tigecycline did demonstrate inferiority when compared with imipenem/cilastatin in a Phase 3 trial of nosocomial ventilator-associated pneumonia-a common site for Acinetobacter infections.
Susceptibility data for tigecycline versus UK pathogens are largely limited to single-centre studies or those focused on bacteraemia, a setting where the drug may be limited by low serum levels. 5 Other large-scale ongoing mandatory and voluntary UK surveillance programmes [Mandatory MRSA, 6 Labbase 7 and the European Antimicrobial Resistance Surveillance System (EARSS) 8 ] do not collect information on the activity of tigecycline.
We conducted the first large-scale multicentre surveillance of tigecycline activity and resistance in the UK.
Methods

Selection of sentinel laboratories and isolate collection
Ninety-three UK hospitals/sites were contacted and, from among these, 43 representative sites were chosen, based on agreement and geographical location to collect and test 150 consecutive, clinically significant isolates from hospitalized patients. The species included comprised: (i) all staphylococci, streptococci and enterococci; (ii) oxidase-negative Gramnegative bacilli (i.e. Enterobacteriaceae and Acinetobacter spp. but excluding Salmonella spp. and Shigella spp.); and (iii) Haemophilus spp. and Moraxella catarrhalis. Species excluded were: (i) oxidase-positive Gram-negative bacilli; (ii) anaerobes; (iii) agents of atypical pneumonia including mycoplasmas and Chlamydophila; (iv) Neisseria spp.; and (v) any category III pathogen. Isolates from urine or faeces were excluded, as were duplicate isolates of the same species, from the same patient and isolated within 7 days of the first isolate. Isolate collection was between September 2006 and April 2007. Urinary isolates were excluded because they would otherwise form a large part of the collection whilst the drug is inappropriate for the setting owing to biliary excretion.
Sentinel laboratory testing
Gram-negative bacilli were screened with an oxidase test, and oxidasepositive isolates were discarded. The oxidase-negative isolates were identified with API20E or API20NE strips (bioMérieux, Marcy l'Étoile, France) as appropriate. Staphylococci were differentiated by coagulase reaction. Streptococci and enterococci were identified with Streptex kits (Pro-Lab Diagnostics, Neston, UK) or API-STREP test strip (bioMérieux). Haemophilus influenzae were identified by morphology and their requirement for X and V factors (Thermofisher, Basingstoke, UK). Laboratories tested all isolates by the BSAC disc method 9 versus a panel of antibiotics (see Table 1 ) using discs (Thermofisher) from the same batches, supplied to all hospitals.
Centralized testing
Participating laboratories sent the following isolates to the Antibiotic Resistance Monitoring and Reference Laboratory (ARMRL, London, UK) for central retesting by the BSAC agar dilution method:
10 (i) a random 10% sample comprising every 10th sample collected per laboratory; and (ii) those with unusual resistance profiles, as detailed in Table 2 . UK tigecycline survey 2603 
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The latter group included any isolates with apparently borderline susceptibility to tigecycline based on inhibition zones of ,26 mm for staphylococci/Haemophilus and ,25 mm for Acinetobacter, streptococci, enterococci and Enterobacteriaceae, as compared with then BSAC resistance breakpoints of ,20 mm for Enterobacteriaceae and Acinetobacter, ,21 mm for enterococci, ,25 mm for streptococci and ,26 mm for staphylococci.
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Quality control
Before any of the sentinel laboratories was allowed to test survey isolates they were asked to complete a quality control exercise. This involved disc testing of 10 distributed reference strains by the BSAC method. These comprised: three Klebsiella for which tigecycline MICs were 0.25, 1 and 4 mg/L, respectively; two E. coli for both of which the tigecycline MIC was 0.25 mg/L; two Acinetobacter spp. for which tigecycline MICs were 0.25 and 1 mg/L; one b-haemolytic Lancefield group G Streptococcus spp. for which the tigecycline MIC was 0.25 mg/L and one Staphylococcus aureus for which the tigecycline MIC was 0.125 mg/L. Laboratories were only allowed to proceed with the testing of the survey isolates once 80% of their zone determinations were within 4 mm of the mean zones determined centrally. Also, any quality control isolate where the sentinel laboratory's zone diameter was ≥9 mm different from that centrally determined had to be retested, regardless of the number of zones obtained within 4 mm for the other quality control isolates. Table 3 summarizes the collection: 6151 isolates were obtained from the 43 UK hospitals. Of these, 2460 (39.9%) were S. aureus, of which 40% were methicillin-resistant S. aureus (MRSA); 820 (13.3%) were E. coli, of which 19% were oxyiminocephalosporin resistant and 24% ciprofloxacin resistant; 720 (11.7%) were streptococci; 391 (6.3%) were enterococci, 17% of them vancomycin resistant; 375 (6.1%) were Klebsiella, of which 30% were oxyimino-cephalosporin resistant and 18% ciprofloxacin resistant; 374 (6.0%) were coagulase-negative staphylococci, of which 66% were oxacillin resistant; 244 (4.0%) were Enterobacter, 46% of them oxyimino-cephalosporin resistant; 138 (2.2%) were Proteeae; and 629 (10.2%) belonged to various other Gram-negative species of which 31% were Enterobacteriaceae. Fifty-four percent of isolates were from men, 45% from women, with 1% unknown; the mean patient age was 56 years. Most isolates were from soft tissue/wound infections (33.1%) or blood (29.5%); 64% were from patients who had been in hospital for .48 h.
Results
The sentinel laboratories' disc testing found 12.8% of isolates were apparently non-susceptible to tigecycline by the BSAC disc breakpoints in place at that time (Table 4) with rates of 25% -35% for Acinetobacter spp., b-haemolytic streptococci, Enterobacter and Klebsiella. The disc results also indicated that 0.2% of the S. aureus and 2% of the coagulasenegative staphylococci were non-susceptible to vancomycin, and that 0.3% -3% of Gram-positive cocci were non-susceptible to linezolid, with the highest rate in the a-haemolytic streptococci. Apparent rates of non-susceptibility to oxyiminocephalosporins among Enterobacteriaceae ranged from 13% to 46%, with non-susceptibility to meropenem ranging from 1% to 8% depending on species.
A total of 1603 isolates were received for central MIC testing, 605 as a random sample, 638 on the basis of reduced tigecycline zones and 360 with other unusual non-susceptibilities, as defined in Table 1 .
Among the 902 isolates received as tigecycline susceptible based on the laboratories' disc tests, 881 (97.6%) ( Table 5) were confirmed susceptible by agar dilution. Of the 21 isolates incorrectly identified as susceptible by the disc tests, one was an S. aureus with an MIC of 1 mg/L, three were tigecycline-resistant Enterobacter spp. for which the MIC was 4 mg/L, six were Klebsiella spp. for which the MIC was 2 mg/L, two were Proteus spp. for which the MIC was 16 mg/L, eight Rates of false resistance were much higher than of false susceptibility. One hundred and thirty-six of the 3943 (3%) Gram-positive isolates collected had been found to be resistant in disc tests, but none of these was confirmed as intermediate or resistant; rather, the one MRSA isolate for which the tigecycline MIC was 1 mg/L was found among the isolates submitted as a random sample. The zone of inhibition for this isolate had been recorded by the sender as 26 mm; however, a zone of 24 mm was obtained at the central laboratory confirming the isolate as resistant by disc breakpoints as well as MIC.
Tigecycline resistance (MIC .2 mg/L) was confirmed in 36 of the 49 Gram-negative isolates submitted as resistant (23 Klebsiella, 15 Proteus spp., 7 Enterobacter spp. and 4 E. coli). The majority of the cases (9/13), where tigecycline resistance was not confirmed proved to be Klebsiella spp. intermediate to tigecycline with MICs of 2 mg/L.
Based on MIC results the overall tigecycline resistance rate in Enterobacteriaceae was only 7.5%, or 2.4% if Proteus were discounted as intrinsically resistant, versus the 3.1% found in the laboratories' disc tests. Fully 62% of the isolates found to be tigecycline non-susceptible by the disc method but susceptible by agar dilution gave zones of inhibition within 4 mm of the published zone breakpoints and thus represent a population where a greater rate of categorization errors is to be expected, simply due to experimental variation. 12 In the case of Haemophilus spp. neither the BSAC nor EUCAST has published tigecycline breakpoints. The highest MIC observed for the genus was 1 mg/L with a mode of 0.5 mg/L.
Central testing by agar dilution did not confirm any disc results of non-susceptibility to vancomycin in staphylococci (n¼ 11) or for any Gram-positive species to linezolid (n¼ 19). By contrast, 82% of the Gram-negatives submitted as nonsusceptible to third-generation cephalosporins were confirmed as non-susceptible by agar dilution.
It should be added here that the isolates collected for centralized MIC testing were not a representative sample but biased towards those resistant or borderline susceptible to tigecycline including, for example, those Enterobacteriaceae with zones of ≤24 mm, which was on the BSAC susceptible breakpoint in place at that time. Isolates with MICs or disc zones close to the breakpoints inevitably are more likely to be miscategorized than those with zones or MICs further from a breakpoint, simply due to the experimental error inherent to susceptibility testing methods. 12 If only the isolates collected as the random 10% sample were considered the tigecycline disc breakpoints performed more adequately with 8.0% minor errors, 3.9% major and no very major errors (Table 6 ). This is within the acceptable limits specified by the BSAC or CLSI. Table 4 . Non-susceptibility (%) determined by sentinel laboratories using the BSAC disc testing method 
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Discussion
This study aimed to survey the prevalence of tigecycline nonsusceptibility among clinical isolates from relevant infections in the UK. Those from respiratory infections were included because these indications were then being sought. Subsequently, in a number of countries, including the USA but not Europe, the licence for tigecycline has been extended to include Comprises isolates received as a random sample and those meeting any of the criteria in Table 2 .
b Species non-specific breakpoint. c Excluding Proteus spp. Hope et al.
community-acquired pneumonia. The study sought also to test the ability of the BSAC zone breakpoints in place at that time to categorize isolates in routine use. It was clear that sentinel laboratory disc results significantly overestimated tigecycline non-susceptibility compared with agar dilution tests. Three main factors most likely conspired to cause this discrepancy: (i) disc zone breakpoints are deliberately biased towards recording false non-susceptibility rather than false susceptibility, as the latter has more serious clinical consequences; (ii) the BSAC disc breakpoints were defined using results from a single centre study 14 potentially underestimating the magnitude of inter-centre variation; and (iii) the 15 mg tigecycline disc, released as a global standard, has poor resolution (1 -2 mm) between disc modal zones for adjacent MICs when used with the BSAC disc testing method. 15 Based on the central MIC testing the present surveillance showed low rates of non-susceptibility to tigecycline: ,1% in Gram-positive organisms and E. coli, though with 17.7%-6.8% in Klebsiella and Enterobacter spp. The overall resistance rate was 2.4%. It should moreover be restated that these rates are probably overestimates, since the isolates collected for the centralized testing were biased to include those with zones around, or smaller than, the breakpoint. If only the isolates in the random 10% sample were considered, the overall percentage resistance rate fell to 1.02%.
The only long-term ongoing surveillance programme in the UK monitoring tigecycline MICs for diverse pathogenic bacteria is the BSAC Bacteraemia Programme, 5 which therefore provides the best comparator for the present study albeit with the caveats that: (i) the collection periods are different, with the BSAC based on a calendar year; (ii) the BSAC study only has 23 UK sentinel laboratories compared with 43 sites in this study; and (iii) this study included isolates from sites other than blood. The BSAC data from 2001-06 showed that tigecycline was almost universally active against common Gram-positive pathogens and E. coli, with greater (17.7% -6.8%) non-susceptibility among Klebsiella spp. and Enterobacter spp. Additional UK tigecycline MIC data are available from the Tigecycline Evaluation and Surveillance Trial (TEST) programme for the period 2006 -07, 16 although this included only four UK hospitals and collected isolates from urine, a site not appropriate for tigecycline therapy owing to the drug's largely (59%) biliary excretion. Table 7 compares the percentage tigecycline nonsusceptibilities for the different organism groups as determined here (disc based upon susceptibility corrected with agar dilution), BSAC and TEST in the UK. All three studies found similar rates of tigecycline non-susceptibility, except that the BSAC bacteraemia surveillance found 9.4% non-susceptibility in coagulase-negative staphylococci and 1%-5% in other Gram-positive species, whereas rates were lower here and in TEST. Irrespective of the study, most non-susceptibility was low level, with far more isolates intermediate rather than fully resistant.
Comparison with non-European studies is complicated by the latter using the US FDA tigecycline breakpoints, which are higher than the EUCAST/BSAC values for the Enterobacteriaceae, with values of ≤2 mg/L counting as susceptible and only ≥8 mg/L as resistant. Such breakpoints result in significantly fewer Klebsiella spp. and Enterobacter spp. isolates being categorized as non-susceptible, and published outputs from TEST for global or non-European data 17 -19 then found that only 6% Klebsiella spp. and Enterobacter spp. species were non-susceptible, although MIC 90 values of 2 mg/L indicated that at least 10% would have counted as non-susceptible based on EUCAST criteria.
The present study is the largest UK point prevalence sentinel survey of tigecycline susceptibility to date, with more UK centres than BSAC and TEST combined and including isolates only from infection sites appropriate for tigecycline therapy. The positive finding is that the drug showed good activity: only 2.4% (0.8% excluding Proteus) of isolates were confirmed to be tigecycline resistant, whilst another 1.4% had intermediate resistance. The negative finding is that BSAC tigecycline disc 
